What we do

Developing topical non-pharmacological and non-steroidal treatment for dermatological diseases

The Company

Aileens Pharma is an Italian biotech company founded in June 2018 which is developing topical non pharmacological and non steroidal treatment for dermatological diseases.

Our MISSION is to provide the first Topical treatment with high safety and efficacy profile without the side effects of current pharmacological therapies.

The patients affected by skin disorders ( Atopic Dermatitis, Psoriasis, Seborrheic Dermatitis, Acne etc. ) have a very low quality of life in terms of physical and psychological well-being. Patients with mild to moderate grade disease can be treated with topical therapies. Unfortunately most of these pathologies are chronic, and the long-term side effects of the current pharmacological treatments (corticosteroids, calcineurin inhibitors, etc) increase the patient’s refusal to this kind of drugs. That is why it is so important developing new effective and safe treatments for these disorders.

The first goal is to fill the existing MARGET GAP in PEDIATRIC dermatology, focusing on Atopic Dermatitis.

The most used drugs are corticosteroids and immunosuppressants, which are not free of side effects and often rejected by the patient, on the other hands, the emollients are very mild and not resolutive.

Our Product

Our product wants to challenge the lack of non-pharmacological therapies for Atopic Dermatitis. To make this possible we developed a MEDICAL DEVICE, called LimpiAD, using a PATENTED biotechnology platform (HAS50) involving the use the use of non – phatogenic bacteria, isolated and protected by a “safe deposit” at an international microorganism database.

The functional ingredient is based on cellular Wall of non-pathogenic bacteria, conjugated with mucopolysaccharide acting as carrier. The product acts on the altered patient’s skin microbiota to re-equilibrate the skin homeostasis and physiology thus improving the patient’s clinical condition and quality of life.

In our production Lab, equipped ad hoc, we grow the bacterium and performing the conjugation procedure, with experienced and trained personnel.

Company founder and CEO, Sonia Longo Sormani brings a strong background in the dermatology, having worked various years in this sector, before creating her own company Claride Pharma. With headquarters in Milan, Aileens Pharma has a strong collaboration with the Laboratory of Clinical Microbiology led by Prof. Roberto Di Marco from UNIMOL.

The Company

Aileens Pharma is an Italian biotech company founded in June 2018 which is developing topical non pharmacological and non steroidal treatment for dermatological diseases.

Our MISSION is to provide the first Topical treatment with high safety and efficacy profile without the side effects of current pharmacological therapies.

The patients affected by skin disorders ( Atopic Dermatitis, Psoriasis, Seborrheic Dermatitis, Acne etc. ) have a very low quality of life in terms of physical and psychological well-being. Patients with mild to moderate grade disease can be treated with topical therapies. Unfortunately most of these pathologies are chronic, and the long-term side effects of the current pharmacological treatments (corticosteroids, calcineurin inhibitors, etc) increase the patient’s refusal to this kind of drugs. That is why it is so important developing new effective and safe treatments for these disorders.

The first goal is to fill the existing MARGET GAP in PEDIATRIC dermatology, focusing on Atopic Dermatitis.

The most used drugs are corticosteroids and immunosuppressants, which are not free of side effects and often rejected by the patient, on the other hands, the emollients are very mild and not resolutive.

Our Product

Our product wants to challenge the lack of non-pharmacological therapies for Atopic Dermatitis. To make this possible we developed a MEDICAL DEVICE, called LimpiAD, using a PATENTED biotechnology platform (HAS50) involving the use the use of non – phatogenic bacteria, isolated and protected by a “safe deposit” at an international microorganism database.

The functional ingredient is based on cellular Wall of non-pathogenic bacteria, conjugated with mucopolysaccharide acting as carrier. The product acts on the altered patient’s skin microbiota to re-equilibrate the skin homeostasis and physiology thus improving the patient’s clinical condition and quality of life.

In our production Lab, equipped ad hoc, we grow the bacterium and performing the conjugation procedure, with experienced and trained personnel.

Company founder and CEO, Sonia Longo Sormani brings a strong background in the dermatology, having worked various years in this sector, before creating her own company Claride Pharma. With headquarters in Milan, Aileens Pharma has a strong collaboration with the Laboratory of Clinical Microbiology led by Prof. Roberto Di Marco from UNIMOL.

Our Partners

Aileens Pharma has been financed by two Italian VCs

Panakès Partners

Panakès Partners is a Venture Capital investor that finances medical companies, early stage startup and SMEs, with extremely promising products and great ambition, in Europe and Israel, improving both patient outcomes and healthcare economics. Investments focus on the medical device, diagnostics and healthcare IT fields. Panakès Partners is headquartered in Milan, Italy.

Invitalia Ventures

Invitalia Ventures is the SGR of Invitalia, the National Agency for inward investment and enterprise development. Invitalia Venture SGR manages the Italia Venture I Fund dedicated to equity investments into innovative SMEs and startups.

The fund exclusively co-invests along with national and international private operators.

Panakès Partners

Panakès Partners is a Venture Capital investor that finances medical companies, early stage startup and SMEs, with extremely promising products and great ambition, in Europe and Israel, improving both patient outcomes and healthcare economics. Investments focus on the medical device, diagnostics and healthcare IT fields. Panakès Partners is headquartered in Milan, Italy.

Invitalia Ventures

Invitalia Ventures is the SGR of Invitalia, the National Agency for inward investment and enterprise development. Invitalia Venture SGR manages the Italia Venture I Fund dedicated to equity investments into innovative SMEs and startups.
The fund exclusively co-invests along with national and international private operators.